| Literature DB >> 26669328 |
Eugenia Kraynov1, Amrita V Kamath2, Markus Walles2, Edit Tarcsa2, Antoine Deslandes2, Ramaswamy A Iyer2, Amita Datta-Mannan2, Priya Sriraman2, Michaela Bairlein2, Johnny J Yang2, Matthew Barfield2, Guangqing Xiao2, Enrique Escandon2, Weirong Wang2, Dan A Rock2, Nagendra V Chemuturi2, David J Moore2.
Abstract
An antibody-drug conjugate (ADC) is a unique therapeutic modality composed of a highly potent drug molecule conjugated to a monoclonal antibody. As the number of ADCs in various stages of nonclinical and clinical development has been increasing, pharmaceutical companies have been exploring diverse approaches to understanding the disposition of ADCs. To identify the key absorption, distribution, metabolism, and excretion (ADME) issues worth examining when developing an ADC and to find optimal scientifically based approaches to evaluate ADC ADME, the International Consortium for Innovation and Quality in Pharmaceutical Development launched an ADC ADME working group in early 2014. This white paper contains observations from the working group and provides an initial framework on issues and approaches to consider when evaluating the ADME of ADCs.Mesh:
Substances:
Year: 2015 PMID: 26669328 DOI: 10.1124/dmd.115.068049
Source DB: PubMed Journal: Drug Metab Dispos ISSN: 0090-9556 Impact factor: 3.922